National Guideline Clearinghouse | Comparison of Oncotype DX with multi-gene profiling assays (e.g., MammaPrint, PAM50) and other tests (e.g., Adjuvant! Online, Ki-67 and IHC4) in early-stage breast cancer.

full-text ►

National Guideline Clearinghouse | Comparison of Oncotype DX with multi-gene profiling assays (e.g., MammaPrint, PAM50) and other tests (e.g., <em>Adjuvant! Online</em>, Ki-67 and IHC4) in early-stage breast cancer.





Program in Evidence-based Care

Cancer Care Ontario (CCO)

Guideline Title

Comparison of Oncotype DX with multi-gene profiling assays (e.g., MammaPrint, PAM50) and other tests (e.g.,Adjuvant! Online, Ki-67 and IHC4) in early-stage breast cancer.

Bibliographic Source(s)

Chang M, Ismaila N, Kamel-Reid S, Rutherford M, Hart J, Bedard P, Trudeau M, Eisen A, Molecular Oncology Advisory Committee. Comparison of Oncotype DX with multi-gene profiling assays (e.g., MammaPrint, PAM50) and other tests (e.g., Adjuvant! Online, Ki-67 and IHC4) in early-stage breast cancer. Toronto (ON): Cancer Care Ontario (CCO); 2013 Nov 20. 39 p. (Recommendation report; no. MOAC-2).  [39 references]

Guideline Status

This is the current release of the guideline.

The RECOMMENDATION report, initially the full original Guideline, over time will expand to contain new information emerging from their reviewing and updating activities.

Please visit the Cancer Care Ontario Web site  for details on any new evidence that has emerged and implications to the guidelines.